Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis

BACKGROUND AND OBJECTIVE: Abrocitinib is a Janus kinase 1 inhibitor in development for the treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib population pharmacokinetics in healthy individuals, patients with psoriasis, and patients with AD and the effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojciechowski, Jessica, Malhotra, Bimal K., Wang, Xiaoxing, Fostvedt, Luke, Valdez, Hernan, Nicholas, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095539/
https://www.ncbi.nlm.nih.gov/pubmed/35061234
http://dx.doi.org/10.1007/s40262-021-01104-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095539/
https://www.ncbi.nlm.nih.gov/pubmed/35061234
http://dx.doi.org/10.1007/s40262-021-01104-z

Ejemplares similares